Entinostat clinical trials
Entinostat is named as an intervention in 7 current clinical trials in our China, Mexico and Israel registers. 4 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Hebei Medical University Fourth Hospital (1). The most-studied condition is Breast Cancer.
Where Entinostat is approved
All regulators →- 1 EU orphan designation, most recently for treatment of Hodgkin's lymphoma (10 Jun 2010, positive)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
How Entinostat works
All drug targets →- Histone deacetylase inhibitor InhibitorTarget: Histone deacetylase✓ In ChEMBL and the Guide to Pharmacology
- Breast cancerPhase 3
- Hodgkins lymphomaPhase 2
- Acute lymphoblastic leukemiaPhase 2
- Acute myeloid leukemiaPhase 2
- CancerPhase 2
- CholangiocarcinomaPhase 2
- Chronic myelomonocytic leukemiaPhase 2
- Clear cell renal carcinomaPhase 2
- Colorectal cancerPhase 2
- Lung cancerPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL27759, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 7007, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Entinostat
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Entinostat
- ChEMBL
- CHEMBL27759
- DrugBank
- DB11841
- PubChem CID
- 4261
- CAS number
- 209783-80-2
- FDA UNII
- 1ZNY4FKK9H
- Wikidata
- Q1281020
- Wikipedia
- Entinostat
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Entinostat
7 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Entinostat
14 conditionsAll 14 conditions
| Condition (as registered) | Trials |
|---|---|
| Breast Cancer | 3 |
| HER2-positive Breast Cancer | 1 |
| Hormone Receptor-Positive Breast Cancer | 1 |
| Metastatic Breast Cancer | 1 |
| Locally Advanced or Metastatic Breast Cancer | 1 |
| Soft Tissue Sarcoma | 1 |
| Bladder Cancer | 1 |
| Histone Deacetylase Inhibitor | 1 |
| Entinostat | 1 |
| Chemotherapy | 1 |
| Anatomic Stage III Breast Cancer AJCC v8 | 1 |
| Anatomic Stage IV Breast Cancer AJCC v8 | 1 |
| Breast Adenocarcinoma | 1 |
| HER2/Neu Negative | 1 |
Sponsors
lead sponsor per trialBy country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 6 | 4 |
| Clinical trials in Mexico | 1 | 0 |
| Clinical trials in Israel | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Entinostat trials
How many clinical trials are testing Entinostat?
7 current trials in our China, Mexico and Israel registers name Entinostat (also registered as MS 27-275) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Entinostat trials recruiting patients?
Yes. 4 of the 7 trials are recruiting: 4 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Entinostat clinical trials?
Hebei Medical University Fourth Hospital (1), Tianjin Medical University Cancer Institute and Hospital (1), Sun Yat-sen University (1) and Zhejiang Cancer Hospital (1), among 7 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Entinostat works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Entinostat works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Entinostat (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.